Q-omics provides the consensus-scored MAOB profile across patient tissues and cancer cell-line models. MAOB expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAOB is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MAOB protein abundance shows 26,360 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where MAOB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAOB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAOB survival associations across molecular data types. MAOB RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAOB RNA expression–survival associations across cancer types. High MAOB expression shows unfavorable associations in BLCA, but favorable associations in KIRC, ACC, MESO, ESCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAOB RNA expression.
This table summarizes MAOB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAOB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAOB shows lower tumor expression in BLCA, COAD, HNSC, KICH and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher MAOB RNA expression in tumor versus normal tissue (log2 FC = +1.148, t-test p < 0.001).
This table shows molecular features associated with MAOB in patient tissues and cancer cell lines. In patient samples, MAOB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MAOB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
